New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:37 EDTCAP, ARIA, VSTM, MDR, AFFY, MSI, ZBRA, PCYC, ALNY, CENT, MUX, PAY, ONXX, CELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affymax (AFFY) initiated with an Outperform at JMP Securities... Alnylam (ALNY) initiated with an Outperform at JMP Securities... Celgene (CELG) initiated with an Outperform at JMP Securities... DSW (DSW) initiated with a Buy at Sterne Agee... McDermott (MDR) initiated with a Neutral at HSBC... Onyx Pharmaceuticals (ONXX) initiated with an Outperform at JMP Securities... Pharmacyclics (PCYC) initiated with an Outperform at JMP Securities... Verastem (VSTM) initiated with an Outperform at JMP Securities... VeriFone (PAY) initiated with a Hold at Jefferies... sZebra Technologies (ZBRA) initiated with a Market Perform at Wells Fargo... ARIAD (ARIA) initiated with an Outperform at JMP Securities... McEwen Mining (MUX) initiated with a Buy at Stifel Nicolaus... Motorola Solutions (MSI) initiated with an Outperform at Wells Fargo... CAI International (CAP) initiated with an Outperform at Wells Fargo... Central Garden & Pet (CENT) initiated with a Neutral at SunTrust.
News For AFFY;CELG;ALNY;MDR;ONXX;PCYC;VSTM;PAY;ZBRA;ARIA;MUX;MSI;CAP;CENT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
16:24 EDTAFFYAffymax adopts tax benefit preservation plan
Affymax announced that its board has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code. The company had federal NOLs totaling approximately $481M at December 31, 2013, a substantial portion of which are limited due to a prior “ownership change”. The company’s use of the remaining NOLs could be substantially limited if the company experiences another “ownership change”. In general, an ownership change occurs if there is a cumulative change in a company’s ownership by “5% shareholders” that increases by more than 50 percentage points over the lowest percentage owned by such stockholders at any time during the prior three years on a rolling basis. The company noted that the Rights Plan is designed to serve the interests of all stockholders by helping to protect the company’s ability to use its NOLs to offset future tax liabilities and is similar to plans adopted by other companies with significant tax attributes.
16:22 EDTAFFYAffymax announces 5c per share special distribution
Subscribe for More Information
16:20 EDTAFFYAffymax appoints Jonathan Couchman as CEO
The Affymax board appointed Jonathan M. Couchman as a Class I director of the company and as its president and CEO, and the remaining members of the board have resigned. The company, under the leadership of Couchman, will continue its evaluation of strategic alternatives.
09:43 EDTVSTMVerastem management to meet with Oppenheimer
Meeting to be held in Dallas on December 2 hosted by Oppenheimer.
November 25, 2014
06:21 EDTMSIPanel makers look to secure orders from Motorola in 2015, DigiTimes reports
Motorola is assessing new panel makers going into 2015 as it prepares for stronger shipments, reports DigiTimes. Samsung (SSNLF), LG Display (LPL), Taiwan Display and Innolux are all aiming to secure orders from Motorola in 2015. The company is also continuing to focus on emerging markets with an emphasis on promoting entry-level handsets in India and Brazil. Reference Link
November 24, 2014
07:36 EDTARIAARIAD, STA announce approval of Iclusig in Australia
Subscribe for More Information
November 21, 2014
10:00 EDTZBRAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Best Buy (BBY) upgraded to Outperform from Market Perform at Telsey Advisory... BlackRock (BLK) upgraded to Outperform from Market Perform at Bernstein... Cerner (CERN) upgraded to Outperform from Market Perform at Cowen... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... Lockheed Martin (LMT) upgraded to Neutral from Sell at UBS... Teekay Offshore Partners (TOO) upgraded to Buy from Neutral at Citigroup... Trinity Industries (TRN) upgraded to Buy from Neutral at Longbow... Zebra Technologies (ZBRA) upgraded to Overweight from Neutral at JPMorgan... Ross Stores (ROST) upgraded to Hold from Sell at Maxim... St. Jude Medical (STJ) upgraded to Outperform from Market Perform at Cowen... Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Sony (SNE) upgraded to Overweight from Neutral at JPMorgan.
07:03 EDTVSTMVerastem presents 'encouraging' data from VS-6063 study
Verastem announced four poster presentations at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain. “We are pleased that the safety and pharmacokinetic profile observed in our Phase 1 study of VS-6063 in Japanese patients was consistent with that seen in the US Phase 1 study, permitting the inclusion of Japanese sites in COMMAND, the registration-directed study of VS-6063 in patients with mesothelioma following frontline chemotherapy. Also, we noted that the one patient in the Phase 1 study with relapsed mesothelioma appeared to receive clinical benefit with disease stabilization of almost 6 months,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “Relapsed mesothelioma is highly aggressive with reported median progression free survival of six weeks in controlled clinical trials. The encouraging data reported here from the combination of VS‐6063 and VS‐5584 in pre-clinical models of mesothelioma offers a novel therapeutic approach in this setting. We look forward to initiating a new clinical study evaluating the combination of these two agents in patients with relapsed mesothelioma in the first quarter of 2015.”
06:10 EDTZBRAZebra Technologies upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Zebra Technologies to Overweight citing a favorable risk/reward despite near-term integration risk from the Motorola enterprise business acquisition. The firm raised its price target for shares to $87 from $75.
06:04 EDTCELGCelgene receives positive CHMP opinion for OTEZLA
Celgene announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, or PDE4, in two therapeutic indications, for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light, or PUVA; alone or in combination with Disease Modifying Antirheumatic Drugs, or DMARD, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
November 19, 2014
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
07:52 EDTALNYInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
14:02 EDTMUXMcEwen Mining to host conference call
Conference call to discuss the current gold price, market conditions and the mining industry will be held on November 21 at 2 pm. Webcast Link
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
November 17, 2014
17:03 EDTALNYAlnylam presents new pre-clinical data on RNAi therapeutic programs
Subscribe for More Information
07:16 EDTONXX, VSTM, CELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
07:09 EDTALNYAmerican Heart Association to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use